Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Advances in treatments for haematologic malignancies from the Sarah Cannon Resea...
Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA
Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (3/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Advances in treatments for haematologic malignancies from the Sarah Cannon Resea...
Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA
Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (2/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Advances in treatments for haematologic malignancies from the Sarah Cannon Resea...
Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA
Advances in treatments for haematologic malignancies from the Sarah Cannon Research Institute presented at ASH 2012 (1/5) ( Dr Ian Flinn - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Multiple myeloma advances for the future suggested by phase I clinical research
Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA
Multiple myeloma advances for the future suggested by phase I clinical research ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Advances in myeloid disease from ASH 2012 from the Sarah Cannon Research Institu...
Dr Michael Savona - Sarah Cannon Research Institute, Nashville, USA
Advances in myeloid disease from ASH 2012 from the Sarah Cannon Research Institute ( Dr Michael Savona - Sarah Cannon Research Institute, Nashville, USA )
20 Dec 2012
Investigation of Ki67 biomarker
Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada
Investigation of Ki67 biomarker ( Dr Torsten Nielsen - University of British Columbia, Vancouver, Canada )
17 Dec 2012
A need for clarity in clinical trial end points
Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA
A need for clarity in clinical trial end points ( Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA )
13 Dec 2012
Expanding international collaboration at IFOM
Prof Marco Foiani – IFOM – University of Milan, Italy
Expanding international collaboration at IFOM ( Prof Marco Foiani – IFOM – University of Milan, Italy )
21 Nov 2012
Perception of inequalities in care and cancer registries
Sir Michael Richards – Department of Health, UK
Perception of inequalities in care and cancer registries ( Sir Michael Richards – Department of Health, UK )
15 Nov 2012
Development of clinical trials and biobanks
Prof Hani Gabra – Imperial College London, UK
Development of clinical trials and biobanks  ( Prof Hani Gabra – Imperial College London, UK )
15 Nov 2012
Participation in clinical trials
Richard Stephens – VNCRI and NCRN Consumer Liaison Groups
Participation in clinical trials ( Richard Stephens – VNCRI and NCRN Consumer Liaison Groups )
14 Nov 2012
A multi-discipline approach to personalised medicine
Prof Vincenzo Valentini – President of ESTRO; Prof Peter Naredi – ESSO, Former P...
A multi-discipline approach to personalised medicine ( Prof Vincenzo Valentini – President of ESTRO; Prof Peter Naredi – ESSO, Former President; Prof Paolo Casali – ESMO, Executive Board Member )
22 Oct 2012